Concerns about data reporting and interpretation in " Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial"

Journal of Psychiatric Research

Volumn 46, Issue 5, 2012, Pages 692-693

  Marks, David M ^a   Abramowitz, Jonathan S ^b   Spielmans, Glen I ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c METROPOLITAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITIFADINE; ANTIDEPRESSANT AGENT; PLACEBO; QUETIAPINE;

BIPOLAR I DISORDER; BIPOLAR II DISORDER; DATA ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INFORMATION PROCESSING; LETTER; MAJOR DEPRESSION; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84859829839     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.02.002     Document Type: Letter

References (7)

1. Dawdy P. Comments on ''Efficacy of quetiapine monotherapy in Bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)'' by Dr Thase and colleagues. Journal of Clinical Psychopharmacology 2008, 28(3):367-368.
2. Marks D.M., Pae C.-U., Patkar A.A. Triple reuptake inhibitors: the next generation of antidepressants. Current Neuropharmacology 2008, 6:338-343.
3. Shadish W.R., Sweeney R.B. Mediators and moderators in meta-analysis: There's a reason we don't let dodo birds tell us which psychotherapies should have prizes. Journal of Consulting and Clinical Psychology 1991, 59:883-893.
4. Spielmans G.I., Pasek L.F., McFall J.P. What are the active ingredients in cognitive and behavioral psychotherapy for anxious and depressed children? A meta-analytic review. Clinical Psychology Review 2007, 27:642-654.
5. Thase M.E., Macfadden W., Weisler R.H., Chang W., Paulsson B., Khan W. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebocontrolled study (the BOLDER II study). Journal of Clinical Psychopharmacology 2006, 26:600-609.
6. Tran P., Skolnick P., Czobor P., Huang N.Y., Bradshaw M., McKinney A., et al. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Research 2012, 46:64-71.
7. Turner E.H., Matthers A.M., Linardatos E., Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 2008, 358:252-260.